tradingkey.logo

Nexalin Technology Inc

NXL
View Detailed Chart

0.935USD

+0.145+18.42%
Close 09/19, 16:00ETQuotes delayed by 15 min
16.28MMarket Cap
LossP/E TTM

Nexalin Technology Inc

0.935

+0.145+18.42%
Intraday
1m
30m
1h
D
W
M
D

Today

+18.42%

5 Days

+6.72%

1 Month

+24.87%

6 Months

-61.84%

Year to Date

-66.13%

1 Year

+33.46%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
100 / 207
Overall Ranking
217 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
4.000
Target Price
+406.65%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Growing
The company is in a growing phase, with the latest annual income totaling USD 168.72K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 348.06.
Overvalued
The company’s latest PE is -1.23, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.88M shares, decreasing 10.83% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 159.88K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.05.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Ticker SymbolNXL
CompanyNexalin Technology Inc
CEOMr. Mark White
Websitehttps://nexalin.com
KeyAI